PDS Biotechnology Corporation (NASDAQ:PDSB) will use its presentation at the prestigious American Society of Clinical Oncology (ASCO) annual meeting next month to reveal it has observed a 10-out-of-14, or 71% response rate to lead drug PDS0101.
There was one complete response, in a person with anal cancer, and nine partial responses from this difficult-to-treat grouping. The medication is still working for nine out of 10 patients five months on from first dosing.
The latest data come from a phase II evaluation of the PDS drug, which comes from the company’s Versamune platform. The study is being led by the National Cancer Institute.
NetScientific holds 5.75% of the US-listed company.
The oral presentation takes place on June 7. For more information click here.
Dr Ilian Iliev, chef executive of NetScientific and director of PDS, said: “We are pleased to see the additional data that further demonstrate the efficacy of the novel Versamune platform. It represents the significant potential that PDS0101 has with treating HPV-associated cancers.”